Metraipolis › archive › dc_99dac3250feb
ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma — Europe PMC PMID:40830586
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40830586
- DOI
- 10.1038/s41598-[numero omesso]-6
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T12:27:11.217Z
- SHA-256 of the archived text
59b8993ccd04de912f1fb9b4f64e7d0a85f7c786566e759a9c566835c275506b- Stable URL of this page
https://metraipolis.com/documento/dc_99dac3250feb
How to cite
ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma — Europe PMC PMID:40830586 — Europe PMC (en), https://europepmc.org/article/MED/40830586 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_99dac3250feb (Metraipolis archive dc_99dac3250feb, sha256 59b8993ccd04de912f1fb9b4f64e7d0a85f7c786566e759a9c566835c275506b)
BibTeX
@misc{dc99dac3250feb,
title = {ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma — Europe PMC PMID:40830586},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40830586},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_99dac3250feb; sha256 59b8993ccd04de912f1fb9b4f64e7d0a85f7c786566e759a9c566835c275506b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40830586. Agents can read the archived copy with the MCP tool read_document.